Patients who suffered COVID-19 during their anti-IL-23 treatment achieved full recovery from COVID-19 and remained asymptomatic or developed mild symptoms, even some at risk of severe COVID-19 development (46–48). This evidence concerns the gene IL23A and COVID-19.